Combination Therapy for the Treatment of Diffuse Midline Gliomas (NCT05009992)
A Combination Therapy Trial Using an Adaptive Platform Design for Children and Young Adults With Diffuse Midline Gliomas (DMGs) Including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression
🩺 Plain-English Summary (8th-Grade Level)
This phase II trial determines if the combination of ONC201 with different drugs is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes for participants with DMGs, and there are few treatment options. This trial will utilize an adaptive platform design in that the different treatment arms for each cohort will be opened and closed based on ongoing preclinical investigation as well as evolving outcome data from the trial. Novel agents will be continuously added to this study as pre-clinical data emerge to suggest additive or synergistic activity when combined ONC201. Should a novel agent not have an RP2D at the time of incorporation into this study, a phase 1 lead-in will be performed prior to initiation of combination therapy (via study amendment).
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 2 Years to 39 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (32 Sites)
Showing the first 25 of 32 sites.
- University of Alabama at Birmingham — Birmingham, Alabama
- Children's Hospital Los Angeles — Los Angeles, California
- University of California, San Diego / Rady Children's Hospital, San Diego — San Diego, California
- University of California, San Francisco — San Francisco, California
- Children's National Hospital — Washington D.C., District of Columbia
- Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois
- Indiana University Riley Children's Hospital — Indianapolis, Indiana
- Johns Hopkins University — Baltimore, Maryland
- Dana-Farber Cancer Institute Harvard University — Boston, Massachusetts
- University of Michigan — Ann Arbor, Michigan
- Children's Hospital Minnesota — Minneapolis, Minnesota
- Washington University in St. Louis — St Louis, Missouri
- Hackensack Meridian Health — Hackensack, New Jersey
- New York University — New York, New York
- Duke University — Durham, North Carolina
- Nationwide Children's Hospital — Columbus, Ohio
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- University of Utah — Salt Lake City, Utah
- Seattle Children's Hospital — Seattle, Washington
- John Hunter Children's Hospital — New Lambton Heights, New South Wales
- The Children's Hospital at Westmead — Westmead, New South Wales
- Queensland Children's Hospital — South Brisbane, Queensland
- Monash Children's Hospital — Clayton, Victoria
- The Royal Children's Hospital Melbourne — Melbourne, Victoria
- Perth Children's Hospital — Nedlands, Washington
📞 Contact the Study Coordinator
Phone: (415) 502-1600
Email: PNOC022@ucsf.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diffuse Intrinsic Pontine Glioma
- Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors — Seattle, Washington
- Fimepinostat in Treating Brain Tumors in Children and Young Adults — Los Angeles, California
- FUS Etoposide for DMG — New York, New York
- Molecular Analysis of Samples From Patients With Diffuse Intrinsic Pontine Glioma and Brainstem Glioma — Washington D.C., District of Columbia
- rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG — Orange, California
- C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) — Houston, Texas
Explore by condition: All Diffuse Intrinsic Pontine Glioma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.